Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tipifarnib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA known ✓ | P49354 | 15/20 | 0.80 |
| ▸ | FNTB known ✓ | P49356 | 15/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.76 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tipifarnib SCHEMBL22772860 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL30436988 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL29371885 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL8097 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL29352433 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL23633189 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL4429738 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL21544535 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL22468601 | 0.96 | FNTA (0.74) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL12021666 | 0.95 | FNTA (0.72) | FNTAFNTBCYP3A4PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 977 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| WO-2021007551-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-01-14 | — | — | WO | claimed |
| EP-1931677-B1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-20 | — | — | EP | claimed |
| WO-2015194710-A1 | COMPOSITION COMPRISING MESENCHYMAL STEM CELLS TREATED WITH STAT3 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING IMMUNE DISEASES | 가톨릭대학교 산학협력단 | 2015-12-23 | — | — | WO | claimed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| EP-2362218-B1 | METHODS OF MONITORING THE EFFICACY OF FARNESYLTRANSFERASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-27 | — | — | EP | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130303564-A1 | METHOD FOR TREATING A NEURODEGENERATIVE DISORDER | RUSH UNIVERSITY MEDICAL CENTER | 2013-11-14 | — | — | US | claimed |
| US-8557847-B2 | Synergistic modulation of FLT3 kinase using a FLT3 inhibitor and a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-10-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-1094839-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH $i(IN VIVO) RADIOSENSITIZING PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-02 | — | — | EP | claimed |
| EP-1094815-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING ARTHROPATHIES | Janssen Pharmaceutica N.V. (BE) | 2001-05-02 | — | — | EP | claimed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | claimed |
| EP-0988038-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-03-29 | — | — | EP | claimed |
| US-6037350-A | USEFUL AS ANTICANCER AGENTS FOR TUMORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2000-03-14 | — | — | US | claimed |
| WO-2000001386-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS FOR TREATING ARTHROPATHIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-13 | — | — | WO | claimed |
| WO-2000001411-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH IN VIVO RADIOSENSITIZING PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-13 | — | — | WO | claimed |
| WO-1998055124-A1 | (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-10 | — | — | WO | claimed |
| EP-0865440-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-09-23 | — | — | EP | claimed |
| WO-1997021701-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITING (IMIDAZOL-5-YL)METHYL-2-QUINOLINONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885CYP3A4 3651/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885CYP3A4 3651/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | FNTA 2042/4885FNTB 3483/4885CYP3A4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.